Nimotuzumab Plus Paclitaxel and Cisplatin as a 1(st)-Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II Study

The effect of anti-epidermal growth factor receptor targeted treatment in esophageal squamous cell carcinoma (ESCC) is still unclear. We conducted a prospective phase II study of paclitaxel, cisplatin, and nimotuzumab (TPN) as a first-line treatment for unresectable or metastatic ESCC and the object...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaodong, Jia, Jun, Lu, Ming, Wang, Xicheng, Gong, Jifang, Li, Jie, Li, Jian, Li, Yan, Zhang, Xiaotian, Lu, Zhihao, Zhou, Jun, Yu, Jing, Sun, Zhiwei, Yang, Ying, Liu, Chuanling, Xiao, Yanjie, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485235/
https://www.ncbi.nlm.nih.gov/pubmed/31031851
http://dx.doi.org/10.7150/jca.28659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485235/
https://www.ncbi.nlm.nih.gov/pubmed/31031851
http://dx.doi.org/10.7150/jca.28659

Ejemplares similares